Three directors join Cobra board
This article was originally published in Scrip
Cobra Biologics, a manufacturer of biologics and pharmaceuticals, has appointed three non-executive directors to its board: Elisabeth Lindner, chair and CEO of Biosource Europe and a board member of BioInvent International, KaroBio and Pharmalink; Professor Carl Sundberg, a licensed physician and associate professor at the department of physiology & pharmacology at Karolinska Institute in Stockholm, Sweden, and co-founder of the Karolinska Investment Fund; and Jinyue Wang, founder and managing partner of 3N Partners (an investment partnership focused on life science/clean-tech investment), and a specialist M&A advisor to the pharmaceutical sector.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.